Evaluating patient responses to omalizumab in solar urticaria

Photodermatol Photoimmunol Photomed. 2019 Jan;35(1):57-65. doi: 10.1111/phpp.12434. Epub 2018 Nov 25.

Authors

Liezel L Griffin¹, Ann K Haylett^{1

2}, Lesley E Rhodes^{1

2}

Affiliations

¹ Centre for Dermatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
² Photobiology Unit, Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, School of Biological Sciences, The University of Manchester, Manchester, UK.

PMID: 30338865
DOI: 10.1111/phpp.12434

No abstract available

Publication types

Case Reports
Evaluation Study
Letter

MeSH terms

Adult
Female
Humans
Male
Middle Aged
Omalizumab / administration & dosage*
Omalizumab / adverse effects
Quality of Life*
Sunlight / adverse effects*
Urticaria / drug therapy*
Urticaria / etiology*
Urticaria / pathology

Substances

Omalizumab

Grants and funding

NIHR Manchester Biomedical Research Centre